908 Devices Inc.
MASSHealthcareNASDAQMedical Devices
Scan Results
Daily timeframe908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company carries a $405.5M market cap, placing it firmly in the small-cap category. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample.
Market Cap
$405.5M
Beta
0.68
P/E (TTM)
—
P/E (Fwd)
-32.70
EPS (TTM)
$-0.93
EPS (Fwd)
$-0.30
ROE
-24.9%
ROA
-6.8%
Cash
$101.5M
Total Debt
$4.3M
Free CF
$18.7M
52W Change
76.3%
Annual Financials
Cash vs Debt
Where MASS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MASS finished 34.68% above its 150-day moving average ($7.67) and 42.88% above its 200-day moving average ($7.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MASS overbought or oversold?
At the September 3, 2026 close, MASS's RSI(14) was 53.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
908 Devices Inc. holds $101.5M in cash against $4.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $18.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -24.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $46.9M to $56.2M.
MASS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MASS.